Background: A modified Delphi approach was used to identify a consensus on practical recommendations for the use of non-pharmacological targeted temperature management in patients with intracerebral haemorrhage, subarachnoid haemorrhage, or acute ischaemic stroke with non-infectious fever (assumed neurogenic fever). Methods: Nine experts in the management of neurogenic fever participated in the process, involving the completion of online questionnaires, face-to-face discussions, and summary reviews, to consolidate a consensus on targeted temperature management. Results: The panel's recommendations are based on a balance of existing evidence and practical considerations. With this in mind, they highlight the importance of managing neurogenic fever using a single protocol for targeted temperature management. Targeted temperature management should be initiated if the patient temperature increases above 37.5 C, once an appropriate workup for infection has been undertaken. This helps prevent prophylactic targeted tem-
Delphi approach was appropriate to gather an expert consensus. To aid in the development of future investigations, the panel provides recommendations for data gathering.
Keywords: stroke; subarachnoid hemorrhage; intracerebral hemorrhage; Delphi technique Targeted temperature management (TTM) is the process of controlling the core body temperature at a specific level. It can be used to achieve hypothermia (TTM hypo ) or maintain normal body temperature (TTM norm ). TTM has been used in several clinical situations, such as out-of-hospital cardiac arrest, traumatic brain injury (TBI), and cerebral vascular accidents, in an attempt to reduce neurological damage and enhance functional outcomes. 1 The evidence base for TTM use in patients with intracerebral haemorrhage (ICH), subarachnoid haemorrhage (SAH), or acute ischaemic stroke (AIS) is limited and difficult to interpret given the range of TTM methods used, the different target temperatures used, the heterogeneity of the patient groups, and the presence or absence of neurogenic or infectious fever. A similar amount of heterogeneity exists in the limited number of clinical guidelines published in France and the USA. Fever is common in critically ill patients with neurological conditions. 2, 3 In those with AIS or TBI, fever can contribute to secondary brain injury, and is associated with poorer functional outcomes and higher morbidity and mortality. 4e6 Fever has an infectious cause in about half of all cases. 2, 3, 7, 8 It has also been shown to have a strong independent association with poor outcomes. 7, 9, 10 Most evidence on fever prevention in patients in critical care is observational in nature, so the specific role fever plays in causing secondary brain injury is unclear. The Impact of Fever Prevention in Brain Injured Patients study (NCT02996266) is a US study that may provide some answers to this question, as it is designed to assess the impact of fever prevention on fever burden and short-and long-term neurological outcomes in brain-injured patients. 11 The goal of this modified Delphi consensusd'establishing consensus in health outcomes (ECHO) for TTM in patients with neurogenic fever'dwas to identify common expert practice recommendations for the use of non-pharmacological TTM in patients with ICH, SAH, or AIS who develop fever. The panel of experts were drawn from UK centres and reflect UK-specific practice, although their recommendations may be extrapolated to other high-income countries with similar healthcare systems.
Methods
A modified Delphi consensus approach was used, which involved a combination of online questionnaires, a face-toface meeting, and post-meeting reviews. The process consisted of two rounds of a Delphi questionnaire (questions are in supplementary data) plus a final validation stage, as shown in Table 1 . Rounds 1 and 2 were conducted at a face-to-face meeting held at the De Vere Grand Connaught Rooms in London on July 5, 2017. P.J.D.A. acted as Chair, with an independent Delphi facilitator moderating the meeting. After the initial meeting, the outcomes report (Round 3) and manuscript validations were conducted asynchronously, with documents shared by e-mail and feedback collected from each participant independently by the facilitator. The agreed cut-off of for the consensus was 70% of experts in agreement; this was in keeping with recent consensus initiatives in this field. 12 
Participants
A total of nine experts in the management of neurogenic fever participated in the consensus process. The participants were selected on the basis of their clinical role, and their experience of managing patients with ICH, SAH, and AIS; managing fever in these patients; and using TTM. The nine participants were drawn from leading intensive and neurocritical care groups in the UK. Five participants attended Rounds 1 and 2. Of these five participants, one felt that they had insufficient breadth of relevant expertise to respond to the questions, and therefore, withdrew from voting to avoid bias. This participant did, however, engage in the discussions and provided insight into infection-related issues. Nine participants were involved in the final manuscript validation.
Rounds 1 and 2 questions
Statements and questions for each round were prepared by the facilitator in consultation with P.J.D.A. and delivered by SurveyMonkey ® to each attendee's e-mail address for them to complete anonymously online and without collaboration whilst at the meeting. Statements and questions were informed by a literature search; the search yielded very few publications relevant to the specific topics under discussion, and these were not shared with the expert panel. Round 1 comprised 25 statements and questions related to the clinical use of TTM for neurogenic fever in patients with ICH, SAH, or AIS. These had been created in consultation with the meeting Chair. The majority of Round 1 questions were in a multiple-choice format, with two free-text questions designed to elicit information and one ranking question. All questions were mandatory, and included a comment box where participants could provide additional comments or insights.
Pooled responses to the Round 1 questions were displayed on screen to the whole group, and the results and comments were discussed. All responses were reviewed and discussed regardless of the level of consensus. Where consensus (!70% agreement) was achieved, the discussion focused on improvements in the phrasing or scope of the initial statement to arrive at a final statement that clearly captured the consensus views of all experts. Where consensus was not reached, a detailed facilitated discussion was undertaken to identify the reasons for the lack of agreement. From these discussions, 14 revised or new statements or questions were identified, which the participants addressed and voted on in Round 2.
Round 3 and final validation
The responses from the meeting were captured in a summary document that showed how the consensus evolved at the meeting. For Round 3, this summary was distributed to all participants via e-mail, with meeting attendees asked to confirm the accuracy of the discussion and non-attendees asked to add their opinions to the document. The additional comments from non-attendees were collated and reviewed. Areas requiring additional discussion were identified, and the process for addressing these was guided by P.J.D.A. A manuscript was created, structuring the recommendations, adding additional narrative, and providing context. This manuscript was distributed to all participants for review and final validation.
Results
The results of the final consensus agreements are presented in Table 2 . The debate and considerations behind these agreements are captured in the discussion section to provide a broader context, in which they can be properly reviewed.
A detailed debate on the definition of neurogenic fever was not undertaken; however, the group established that, for the purposes of this Delphi consensus, neurogenic fever equated with non-infectious fever.
Discussion
This consensus discussion approach was necessary because of the scant and heterogeneous nature of existing published evidence. The modified Delphi approach sought to combine the advantages of a traditional Delphi process (specifically, the structured information flow and anonymous submission of Table 2 Summary of recommendations. AIS, acute ischaemic stroke; ICH, intracerebral haemorrhage; MOHS, modified Oxford handicap scale; SAH, subarachnoid haemorrhage; TTM, targeted temperature management
Topic

Level of consensus
Core-temperature measurement Core-temperature measurement is important to enable the effective identification, treatment, and monitoring of neurogenic fever.
100% Round 2
Core temperature should be measured continuously, or at a minimum hourly, in patients with ICH, SAH, or AIS.
100% Round 1
Neurogenic fever and TTM As neurogenic fever is associated with poor patient outcomes amongst patients with ICH, SAH, or AIS, treating it is important.
TTM norm is appropriate for the treatment of neurogenic fever in adult patients with ICH, SAH, and AIS. 75% ICH; 100% SAH, AIS Round 1 From a practical perspective, it is appropriate to have a single protocol for TTM of neurogenic fever in ICH, SAH, and AIS.
100% Round 2
When to use TTM TTM should be used reactively in patients with ICH, SAH, or AIS in response to neurogenic fever.
100% Round 1
TTM should be initiated if the patient's temperature increases to !37.5 C and infection is excluded. >75% Round 3 TTM should be initiated as rapidly as possibly once fever is detected and if pharmacological treatment has not controlled the temperature within 1 h of administration.
100% Round 2
How to use TTM The target temperature for patients with ICH, SAH, or AIS who develop neurogenic fever is 37.0 C±0.5 C.
TTM should be maintained for as long as there is potential for secondary brain damage. 100% Round 2 The use of an advanced TTM method, enabling precise temperature control, is required to maintain the temperature effectively.
100% Round 1
Shivering Shivering should be managed during TTM.
Outcomes assessment Data on outcomes should be collected for patients with ICH, SAH, or AIS (i) MOHS assessment is recommended at 1 month.
(ii) MOHS and modified Rankin scale assessment should be attempted at 6 months.
100% Round 2 opinion) with those of the nominal group technique (specifically, the ability to actively discuss the responses to the questions, leading to further voting). The focus was on gaining a consensus and expert insight into the usual practice in the UK regarding TTM, which, in this case, relates to TTM norm , with the recommendations focusing on non-pharmacological TTM approaches.
Core-temperature measurement
(i) Core-temperature measurement is important to enable effective identification, treatment, and monitoring of neurogenic fever.
(ii) Core temperature should be measured continuously, or at a minimum hourly, in patients with ICH, SAH, or AIS.
There was no clear agreement amongst the participants on the best site at which to measure core temperature. The lack of a final consensus related to the practical challenges that can exist locally, if the patient was awake or comatose, or how the core-temperature measurements were interpreted at specific sites, especially if these sites are not standard practice.
Guidelines from a French expert panel, whilst recommending a core-temperature measurement for TTM in ICUs, failed to indicate specific sites. 12 Oesophageal or bladder probes are recommended for temperature measurement during TTM after a neurological injury by recent guidelines from the US Neurocritical Care Society (NCS), which also suggest a preference for continuous monitoring. 5 The Delphi participants' recommendations for sites of temperature measurement were split between two non-gold standard sites: the oesophagus and the rectum. The panel felt that whatever site is selected, it should enable continuous, or near continuous, monitoring. However, specific clinical situations may make continuous monitoring impractical and, in such cases, a minimum of hourly measurements is advised.
Neurogenic fever and targeted temperature management (i) As neurogenic fever is associated with poor patient outcomes amongst patients with ICH, SAH, or AIS, treating it is important. (ii) TTM norm is appropriate for the management of neurogenic fever in adult patients with ICH, SAH, or AIS.
Fever is commonly reported in ICH, SAH, and AIS, although incidence rates vary between studies and the cause of fever is often not clearly defined. In a large retrospective US study of fever in patients with brain injuries, 51% were classified as having fever, with fever incidences of 60% for TBI, 54% for aneurysmal SAH, 50% for ICH, and 37% for AIS. 3 All panel members accepted that poor outcomes are associated with neurogenic fever in these patients, given the weight of published evidence, for example, by Scaravilli ; therefore, it should be avoided or treated. A major question regarding the use of TTM in febrile patients with brain injury is the type of TTM that should be used: TTM hypo (maintenance of temperature below 37 C) or TTM norm (maintenance of temperature at 37 C). From the literature, it is difficult to discern the evidence for reactive TTM norm to manage neurogenic fever from the data published on the use of prophylactic TTM norm or TTM hypo for neuroprotection in TBI and stroke. 5, 12, 14, 15 Overall, the panel felt that the evidence for TTM hypo in patients with neurogenic fever in ICH, SAH, and AIS was poor, and that, on balance, hypothermia could be associated with negative outcomes. The panel, therefore, recommended TTM norm for these patients, and hence, the focus of this paper.
There was no detailed discussion of the criteria for TTM hypo .
(iii) From a practical perspective, it is appropriate to have a single protocol for TTM of neurogenic fever in ICH, SAH, and AIS.
Although the panel acknowledged the existence of some differences between the three conditions, they felt that there was enough similarity to allow recommendations to be grouped in a single protocol, especially as it was felt impractical to have more than one. The panel did not consider location of care (ICU or ward) for these patients important, appreciating that such decisions would be dictated by local practice, service availability, and patient needs.
When to use targeted temperature management (i) TTM should be used reactively in patients with ICH, SAH, or AIS in response to neurogenic fever.
The panel felt that TTM should only be used once a patient develops fever, as there is limited evidence to support the use of prophylactic TTM after ICH, SAH, or AIS regardless of core temperature. Prophylactic TTM also carries additional risks, such as masking fever associated with infection, and should therefore be avoided.
(ii) TTM should be initiated if the patient temperature increases to !37.5 C and infection is excluded.
The temperature threshold for TTM was discussed in detail at the meeting and in subsequent review rounds. The threshold debate centred on balancing the need to act as soon as temperature increase is detected, against mitigating the risk of prophylactic TTM use.
In healthy individuals, core temperature is not constant but fluctuates by up to 0.5 C around the 'normal' 37 C average temperature. 16 Although the term fever is commonly understood, no universally accepted definition exists, and it is often used interchangeably with the terms pyrexia or hyperthermia.
2,17
Similarly, there is no accepted temperature threshold that defines the occurrence of fever, with between 5 and 14 different thresholds reported in various studies identified by a literature review. 2 A threshold of !38.3 C is often cited. This equates to 101 F and is based on US recommendations on fever control. 17 The majority of the panel felt that >37.5 C was appropriate and in line with the range agreed for normothermia (see later), although a minority preferred !38 C. The panel also recognised the urgency of expediting the identification and treatment of potentially life-threatening infection as an important step before the use of TTM. Fever should be treated early, regardless of its cause.
(iii) TTM should be initiated as rapidly as possible once fever is detected if pharmacological treatment has not controlled temperature within 1 h of administration.
The panel thought that the evidence for the effectiveness of antipyretic agents, such as paracetamol, in controlling fever in patients with ICH, SAH, or AIS was limited. However, they accepted that, as these agents are widely used as the first option for fever control, it was appropriate to try them, but act swiftly if they yield no benefit within 1 h. The panel advised a more aggressive treatment of temperature if the fever was associated with seizures.
Paracetamol is widely used in ICU patients to treat both fever and pain. A 4 g day À1 dose is often administered as standard, but reports suggest this is frequently ineffective for fever control in patients with brain injury. 1 Other studies using a higher dose (6 g day À1 ) have shown small but important reductions in temperature. 1, 18, 19 Many of these studies administered paracetamol to all patients, not only those with fever, so it is difficult to draw firm conclusions on its use in fever.
There is little evidence on functional outcomes in the use of paracetamol in patients with acute stroke. 20e22 However, one study suggested that stroke patients with fever on admission experience functional outcome benefits from paracetamol use. 23 The alternative antipyretic agent, ibuprofen, shows no greater efficacy than paracetamol, and can be associated with an increased bleeding risk. 18, 24 When NSAIDs are used, one small randomised study on neurosurgical ICU patients suggested that temperature control is significantly better with a low-dose continuous infusion of diclofenac than with intermittent bolus doses of NSAIDs. 25 The panel debated the relative benefit of high-dose paracetamol compared with the risk of possible side-effects. The panel also discussed the possibility of augmented fever control by combing paracetamol with external cooling via fans. No specific recommendations emerged from these discussions.
How to use TTM
(i) The target temperature for patients with ICH, SAH, or AIS who develop neurogenic fever is 37.0 C±0.5 C.
The specific definition of normothermia recommended by the panel is 37.0 C±0.5 C, with a target temperature plus range believed to offer clear parameters within which to control temperature. Strict control of core temperature to avoid fluctuations may be beneficial. Evidence from a post hoc analysis of the Eurotherm3235 Trial on TTM to 32e35 C in patients with TBI showed that temperature fluctuations during the first 48 h cooling period was associated with worse neurological outcomes only in the control group. Patients in the control group were managed to normothermia and had more episodes of temperature in excess of 38 C than those in the hypothermia group. 26 (ii) TTM should be maintained for as long as there is potential for secondary brain damage.
The panel debated various durations of TTM in an attempt to provide specific guidance, but no consensus was achieved. The suggested durations included 48 h, 72 h, 3e5 days, or based on need. Overall, the group felt that it was difficult to provide categorical recommendations, especially as clinical situations, such as whether the patient is awake or comatose, could impact the decision. The panel also recognised that clinicians must be vigilant for the possibility of infection occurring during the period of TTM.
The NCS TTM guidelines also addressed the question of TTM duration by comparing the benefits of a pre-specified duration of TTM with a goal-based approach for patients with TBI. Their conditional recommendation, based on lowquality evidence, was to suggest longer duration of TTM for severe TBI patients should ICP control be the goal. 5 (iii) The use of an advanced TTM method enabling precise temperature control is required to maintain temperature effectively.
The panel felt that accurate and consistent temperature control required advanced TTM methods, although there was no detailed debate on what specific advanced methods were preferred.
The two main non-pharmacological advanced TTM methods currently in use are surface cooling and endovascular cooling. Surface-cooling methods include air-circulating blankets, water-circulating blankets, and hydrogel-coated water-circulating pads, whilst endovascular cooling uses i.v. heat exchange catheters. Endovascular cooling can be associated with additional risks similar to those found with invasive central vascular access. 1 The recent NCS guidelines made a strong recommendation for the use of intravascular catheters or gel pads if such catheters are not available to maintain constant temperature.
5
The panel also considered inadvertent overcooling, when the core temperature decreases below the normothermic range of 37.0 C±0.5 C. This can occur when less advanced TTM methods are used. In such a situation, rewarming to normothermia should be slow and controlled at a rate of 0.25 C per hour.
Shivering
(i) Shivering should be managed during TTM.
All panellists recommended that shivering should be managed, as it can cause cerebral and metabolic stress, and negate the beneficial effects of TTM. However, there was no clear agreement on the method(s) that should be used to manage shivering. The approaches to shivering control suggested by the panel included pharmacological and nonpharmacological methods, either alone or in combination: sedation, counter-warming (not all members of the panel were aware of counter-warming, so felt unable to comment on its value), neuromuscular block, and a combination of the above.
Shivering is a physiological heat-generating mechanism that occurs to maintain core temperature at the set-point temperature of the hypothalamus. 24 As about 20% of the thermoregulatory drive for shivering comes from the skin, counter-warming of the skin on the head, hands, arms, or face (use of gloves, hats, socks, and blankets) can reduce shivering without pharmacological intervention, whilst allowing the core temperature to be controlled. 27 Paracetamol, magnesium, sedatives (such as dexmedetomidine or buspirone), opioids (such as pethidine, tramadol, and naloxone), neuromuscular blocking agents, and alpha-2 adrenergic agonists (such as clonidine and dexmedetomidine) have all been used to treat shivering pharmacologically. 5, 27 Decisions may be guided by the level of consciousness of the patient (e.g. paracetamol and clonidine may be more appropriate in patients who are awake) or the risks of pharmacological interventions (e.g. clonidine can cause bradycardia and hypotension).
Shivering is well recognised as a problem with TTM. Like the Delphi panel, the NCS also suggested the prompt treatment of shivering during TTM in brain-injury patients, but specifically suggested a stepwise approach, starting with non- sedating interventions, such as counter-warming, before the use of sedatives or neuromuscular block. 5 The NCS also recommends the use of a scale, such as the bedside shivering assessment scale, to help characterise shivering and support decision-making. 5 Outcomes assessment should be attempted at 6 months.
Given the lack of consistent evidence on TTM use in patients with ICH, SAH, or AIS, the collection of outcome data at specific time points could support better audit and guide further recommendations on TTM use. These recommendations should, however, balance the value of the data against the practicality of data collection.
Conclusions
This consensus project was based on the shared desire to develop a series of practical recommendations based on expert opinion to support clinicians less experienced in using TTM to manage neurogenic fever in ICH, SAH, and AIS patients. The modified Delphi approach utilised was designed to overcome some of the gaps in published evidence on TTM in these specific situations and to allow the recommendations to be practically focused.
Other expert panels have considered similar, although not identical, questions using population, intervention, comparison, outcomes and grades of recommendation, assessment, development, and evaluation methodologies, and have come up with differing opinions. A range of guidelines for the management of patients with ICH, SAH, or AIS, or the use of TTM in neurological patients, exists, but these provide no, or conflicting, recommendations for TTM because of limitations of currently available data. Table 3 summarises the key statements on control of fever or use of TTM from these guidelines. 5,12,22,28e33 The 2017 NCS guidelines on the use of TTM in patients in neurocritical care, for example, recommend using controlled normothermia to reduce fever in those whose fever is refractory to conventional therapy, 5 whilst the French 2017 guidelines on TTM recommend prophylactic normothermia during the early phase of severe ischaemic stroke, hypothermia (35e37 C) in comatose patients with spontaneous ICH to lower ICP, and TTM (to an unspecified temperature) in comatose patients with aneurysmal SAH to lower ICP or improve the neurological outcome. 12 This underscores the challenge of interpreting and extrapolating data to specific clinical situations. Looking more widely at general guidelines on the management of ICH, SAH, and AIS, a similarly mixed picture emerges (Table 3) . On balance, reactive TTM norm appears a rational and consistent recommendation for the management of neurogenic fever in patients with ICH, SAH, or AIS given the range of views. The consensus statements presented here focus on recommendations for a specific group of patients. They do not contain detailed recommendations on the level of care or the situation for comatose vs non-comatose patients. Many of these statements may be influenced by local service structure and practice, and the panel was keen to ensure that the recommendations could be used in any care setting, yet not be so complex or prescriptive as to deter adoption.
The Delphi process has some drawbacks. Although the online questionnaire was completed anonymously and independently, the subsequent group discussion could allow social bias in responses. Several panellists could not attend the meeting, so their input was gathered on the meeting summary document. This approach may have led to an unequal weighting of opinions, with greater weight given to those who attended in person.
Given the heterogeneity of published evidence and clinical guidelines on the use of targeted temperature management to treat fever in patients with intracerebral haemorrhage, subarachnoid haemorrhage, or acute ischaemic stroke, all attendees felt that the agreed recommendations would provide clinical guidance for the development of local protocols for the benefit of clinicians and patients. The next challenge will be to assess their use and the impact on patient outcomes.
